331 related articles for article (PubMed ID: 17481554)
1. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids.
Rubin P; Mollison KW
Prostaglandins Other Lipid Mediat; 2007 May; 83(3):188-97. PubMed ID: 17481554
[TBL] [Abstract][Full Text] [Related]
2. The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets?
Sharma JN; Mohammed LA
Inflammopharmacology; 2006 Mar; 14(1-2):10-6. PubMed ID: 16835707
[TBL] [Abstract][Full Text] [Related]
3. 5-Lipoxygenase products regulate basophil functions: 5-Oxo-ETE elicits migration, and leukotriene B(4) induces degranulation.
Iikura M; Suzukawa M; Yamaguchi M; Sekiya T; Komiya A; Yoshimura-Uchiyama C; Nagase H; Matsushima K; Yamamoto K; Hirai K
J Allergy Clin Immunol; 2005 Sep; 116(3):578-85. PubMed ID: 16159627
[TBL] [Abstract][Full Text] [Related]
4. [Leukotrienes: potential therapeutic targets in cardiovascular diseases].
Bäck M
Bull Acad Natl Med; 2006 Oct; 190(7):1511-8; discussion 1518-21. PubMed ID: 17450683
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of the leukotriene pathway in allergic airway disease.
Montuschi P; Sala A; Dahlén SE; Folco G
Drug Discov Today; 2007 May; 12(9-10):404-12. PubMed ID: 17467577
[TBL] [Abstract][Full Text] [Related]
6. Leukotriene modifiers in the treatment of cardiovascular diseases.
Riccioni G; Capra V; D'Orazio N; Bucciarelli T; Bazzano LA
J Leukoc Biol; 2008 Dec; 84(6):1374-8. PubMed ID: 18794213
[TBL] [Abstract][Full Text] [Related]
7. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.
Singh RK; Gupta S; Dastidar S; Ray A
Pharmacology; 2010; 85(6):336-49. PubMed ID: 20516735
[TBL] [Abstract][Full Text] [Related]
8. Leukotrienes, antileukotrienes and asthma.
Montuschi P
Mini Rev Med Chem; 2008 Jun; 8(7):647-56. PubMed ID: 18537720
[TBL] [Abstract][Full Text] [Related]
9. A review on leukotrienes and their receptors with reference to asthma.
Singh RK; Tandon R; Dastidar SG; Ray A
J Asthma; 2013 Nov; 50(9):922-31. PubMed ID: 23859232
[TBL] [Abstract][Full Text] [Related]
10. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor.
Takasaki J; Kamohara M; Matsumoto M; Saito T; Sugimoto T; Ohishi T; Ishii H; Ota T; Nishikawa T; Kawai Y; Masuho Y; Isogai T; Suzuki Y; Sugano S; Furuichi K
Biochem Biophys Res Commun; 2000 Aug; 274(2):316-22. PubMed ID: 10913337
[TBL] [Abstract][Full Text] [Related]
11. 15-lipoxygenase metabolites play an important role in the development of a T-helper type 1 allergic inflammation induced by double-stranded RNA.
Jeon SG; Moon HG; Kim YS; Choi JP; Shin TS; Hong SW; Tae YM; Kim SH; Zhu Z; Gho YS; Kim YK
Clin Exp Allergy; 2009 Jun; 39(6):908-17. PubMed ID: 19260872
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma.
Drazen JM
Pharmacotherapy; 1997; 17(1 Pt 2):22S-30S. PubMed ID: 9017785
[TBL] [Abstract][Full Text] [Related]
13. [The significance of leukotrienes in pathophysiology of bronchial asthma--therapy perspectives].
Wojnowski P; Patkowski J
Postepy Hig Med Dosw; 1997; 51(5):499-514. PubMed ID: 9489451
[TBL] [Abstract][Full Text] [Related]
14. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.
Izumo T; Kondo M; Nagai A
Life Sci; 2007 Apr; 80(20):1882-6. PubMed ID: 17397875
[TBL] [Abstract][Full Text] [Related]
15. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions.
Bäck M; Dahlén SE; Drazen JM; Evans JF; Serhan CN; Shimizu T; Yokomizo T; Rovati GE
Pharmacol Rev; 2011 Sep; 63(3):539-84. PubMed ID: 21771892
[TBL] [Abstract][Full Text] [Related]
16. Cysteinyl leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in a mouse asthma model.
Wong WS; Zhu H; Liao W
Eur J Pharmacol; 2007 Dec; 575(1-3):134-41. PubMed ID: 17689528
[TBL] [Abstract][Full Text] [Related]
17. 5-Lipoxygenase/cyclooxygenase-2 cross-talk through cysteinyl leukotriene receptor 2 in endothelial cells.
Lötzer K; Jahn S; Kramer C; Hildner M; Nüsing R; Funk CD; Habenicht AJ
Prostaglandins Other Lipid Mediat; 2007 Nov; 84(3-4):108-15. PubMed ID: 17991613
[TBL] [Abstract][Full Text] [Related]
18. Eoxins: a new inflammatory pathway in childhood asthma.
Sachs-Olsen C; Sanak M; Lang AM; Gielicz A; Mowinckel P; Lødrup Carlsen KC; Carlsen KH; Szczeklik A
J Allergy Clin Immunol; 2010 Oct; 126(4):859-867.e9. PubMed ID: 20920774
[TBL] [Abstract][Full Text] [Related]
19. The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists.
Rackal JM; Vender RB
Skin Therapy Lett; 2004 Feb; 9(2):1-5. PubMed ID: 14749843
[TBL] [Abstract][Full Text] [Related]
20. Endothelial cysteinyl leukotriene 2 receptor expression and myocardial ischemia/reperfusion injury.
Moos MP; Funk CD
Trends Cardiovasc Med; 2008 Oct; 18(7):268-73. PubMed ID: 19232956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
